New pricing models for generic medicines to ensure long-term sustainable competition in Europe
Frontiers in Pharmacology · 09.10.2023 · 14
DOI: 10.3389/fphar.2023.1200641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.10.2023. Verfasst von Clement Francois und 6 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille University, Marseille, France. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Price erosion of generic medicines over time as a result of existing pricing policies in combination with increasing operational costs of these products due to high inflation, undermine long-term sustainable competition in European off-patent medicines markets. Therefore, the aim of this study is to identify new potential pricing models for retail generic medicines in Europe, examine their pros and cons, and illustrate them with examples inside or outside the pharmaceutical sector.
Methods
A targeted literature review, one-to-one interviews and a joint advisory board meeting with experts from five European countries were carried out to assess potential pricing models for generic medicines.
Results
We identified ten pricing models that can be applied to generic medicines. The tiered pricing model is viewed as a sustainable solution ensuring competitiveness, but requires market monitoring using a supportive IT infrastructure. De-linking the price of generic medicines from that of the off-patent originator medicine prevents the originator from forcing generic medicines’ prices to unsustainable levels. Higher costs due to inflation can be compensated in the automatic indexation model. Other pricing models that have less implementation potential include the one-in-one/multiple-out model, tax credits, value-based pricing, volume for savings and guaranteed margin/fee models. The hypothecated tax and cost allocation models, which add a patient fee to generic medicines prices, are not likely to be socially acceptable.
Conclusion
When considering a new pricing model for generic medicines, the impact on innovative medicines and the characteristics of the healthcare system in a given country need to be taken into account. Also, there is a need to continuously follow up the level of competition in off-patent medicines markets and to identify sustainability risks.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Aix Marseille University, Marseille, France.
- Putnam PHMR, Paris, France.
- Putnam PHMR, Krakow, Poland.
- Universidad Carlos III, Madrid, Spain.
- Department of Public Health, Babes Bolyai University, Cluj Napoca, Romania.
- NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, CHRC, NOVA University Lisbon, Lisbon, Portugal.
Zitieren
APA
Francois, C., Gawlik, G., Mestre-Ferrandiz, J., Pana, A., Perelman, J., Yfantopoulos, J., & Simoens, S. (2023). New pricing models for generic medicines to ensure long-term sustainable competition in Europe. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1200641
Vancouver
Francois C, Gawlik G, Mestre-Ferrandiz J, Pana A, Perelman J, Yfantopoulos J, et al. New pricing models for generic medicines to ensure long-term sustainable competition in Europe. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1200641
BibTeX
@article{Francois2023,
author = {Francois, Clement and Gawlik, Gabriela and Mestre-Ferrandiz, Jorge and Pana, Adrian and Perelman, Julian and Yfantopoulos, John and Simoens, Steven},
title = {New pricing models for generic medicines to ensure long-term sustainable competition in Europe},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1200641}
}
EUVIMED